Rezultati pretrage - David M. Pariser

Detaljiziraj rezultate
  1. 1
    Topical 0.5% Ivermectin Lotion for Treatment of Head Lice

    Topical 0.5% Ivermectin Lotion for Treatment of Head Lice od David M. Pariser, Terri L. Meinking, Margie Bell, William G. Ryan

    Izdano 2012
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  2. 2
    The Epidemiology, Etiology, and Pathophysiology of Onychomycosis

    The Epidemiology, Etiology, and Pathophysiology of Onychomycosis od Richard K. Scher, Phoebe Rich, Boni E. Elewski, David M. Pariser

    Izdano 2013
    Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  3. 3
    The electric field near human skin wounds declines with age and provides a noninvasive indicator of wound healing

    The electric field near human skin wounds declines with age and provides a noninvasive indicator of wound healing od Richard Nuccitelli, Pamela Nuccitelli, Changyi Li, Suman Narsing, David M. Pariser, Kaying Lui

    Izdano 2011
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  4. 4
    A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis

    A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis od David M. Pariser, Brad Schenkel, Chureen Carter, Kamyar Farahi, T. Michelle Brown, Charles N. Ellis

    Izdano 2015
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  5. 5
    Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States

    Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States od Alexa B. Kimball, Jennifer Schenfeld, Neil A. Accortt, Mary S. Anthony, Kenneth J. Rothman, David M. Pariser

    Izdano 2015
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  6. 6
    Hematologic Safety of Dapsone Gel, 5%, for Topical Treatment of Acne Vulgaris

    Hematologic Safety of Dapsone Gel, 5%, for Topical Treatment of Acne Vulgaris od Warren W. Piette, Susan C. Taylor, David M. Pariser, Michael Jarratt, Pranav Sheth, David J. Wilson

    Izdano 2008
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  7. 7
    Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis

    Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety... od Robert Bissonnette, David M. Pariser, Norman Wasel, Joana Gonçalves, Robert M. Day, Rongdean Chen, Michael Sebastian

    Izdano 2016
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  8. 8
    Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up

    Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follo... od Eduardo Tschen, David S.Y. Wong, David M. Pariser, F E DUNLAP, Anna Houlihan, Mary Beth Ferdon

    Izdano 2006
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  9. 9
    A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis

    A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patient... od Kim Papp, David M. Pariser, Mary Catlin, G. Wierz, Greg Ball, B. Akinlade, Bernhardt Zeiher, James G. Krueger

    Izdano 2015
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  10. 10
    Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis

    Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis od Amy S. Paller, Elaine C. Siegfried, David M. Pariser, Kara Rice, Mona Trivedi, Jan Iles, David H. Collier, Greg Kricorian, Richard Langley

    Izdano 2016
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  11. 11
    Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials

    Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials od Linda Stein Gold, Mark Lebwohl, Jeremy Sugarman, David M. Pariser, Tina Lin, Gina Martin, Radhakrishnan Pillai, Robert J. Israel, Tage Ramakrishna

    Izdano 2018
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  12. 12
    Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials

    Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials od Dee Anna Glaser, Adelaide A. Hebert, Alexander Nast, William Philip Werschler, Lawrence Green, Richard D. Mamelok, Janice Drew, John Quiring, David M. Pariser

    Izdano 2018
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  13. 13
    TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial

    TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial od Seth Forman, David M. Pariser, Yves Poulin, Michael S. Vincent, Steven A. Gilbert, Elizabeth Kieras, Ruolun Qiu, Dahong Yu, Jocelyne Papacharalambous, Christopher Tehlirian, Elena Peeva

    Izdano 2020
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  14. 14
    Etanercept Treatment for Children and Adolescents with Plaque Psoriasis

    Etanercept Treatment for Children and Adolescents with Plaque Psoriasis od Amy S. Paller, Elaine C. Siegfried, Richard Langley, Alice B. Gottlieb, David M. Pariser, Ian Landells, Adelaide A. Hebert, Lawrence F. Eichenfield, Vaishali Patel, Kara Creamer, Angelika Jahreis

    Izdano 2008
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  15. 15
    Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies

    Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies od Mark Boguniewicz, Andrew Alexis, Lisa A. Beck, Julie Block, Lawrence F. Eichenfield, Luz Fonacier, Emma Guttman‐Yassky, Amy S. Paller, David M. Pariser, Jonathan I. Silverberg, Mark Lebwohl

    Izdano 2017
    Preuzmi cijeli tekst
    Revisão
    Spremi u popis
    Spremljeno u:
  16. 16
    Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis

    Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis od Eric L. Simpson, Laurent Eckert, Abhijit Gadkari, Usha G. Mallya, Min Yang, Lauren Nelson, T. Michelle Brown, Matt Reaney, Puneet Mahajan, Isabelle Guillemin, Mark Boguniewicz, David M. Pariser

    Izdano 2019
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  17. 17
    A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis

    A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis od Mark Lebwohl, Stephen K. Tyring, Tiffani K. Hamilton, Darryl Toth, Scott D. Glazer, Naji Tawfik, Patricia A. Walicke, Wolfgang Dummer, Xiaolin Wang, Marvin R. Garovoy, David M. Pariser

    Izdano 2003
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  18. 18
    Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT)

    Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT) od David M. Pariser, Eric L. Simpson, Abhijit Gadkari, Thomas Bieber, David J. Margolis, T. Michelle Brown, Lauren Nelson, Puneet Mahajan, Matthew Reaney, Isabelle Guillemin, Usha G. Mallya, Laurent Eckert

    Izdano 2019
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  19. 19
    Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial

    Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the op... od Diamant Thaçi, Ronald Vender, Menno A. de Rie, Curdin Conrad, David M. Pariser, Bruce Strober, Veerle Vanvoorden, Maggie Haitian Wang, Cynthia Madden, Dirk De Cuyper, Alexa B. Kimball

    Izdano 2023
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  20. 20
    OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results

    OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results od Alexa B. Kimball, Kenneth J. Rothman, Gregory Kricorian, David M. Pariser, Paul S. Yamauchi, Alan Menter, Craig Teller, Girish Aras, Neil A. Accortt, Michele Hooper, Kara Rice, Joel M. Gelfand

    Izdano 2014
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:

Alati za pretragu: